Advances in assay of complement function and activation

Advanced Drug Delivery Reviews

Volumn 63, Issue 12, 2011, Pages 976-987

  Harboe, Morten ^a   Thorgersen, Ebbe Billmann ^a   Mollnes, Tom Eirik ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Activation; Animal; Assay; Complement; Danger signals; Nanoparticles; Neoepitopes

Indexed keywords

ACTIVATION PRODUCTS; ARTIFICIAL MATERIAL; BIOMEDICAL MATERIAL; COMPLEMENT; COMPLEMENT SYSTEMS; DANGER SIGNALS; FLUID-PHASE; IN-VITRO; INFLAMMATORY RESPONSE; NEOEPITOPES; PATHOGEN-ASSOCIATED MOLECULAR PATTERNS; SENSITIVE METHOD;

ANIMALS; BIOCOMPATIBILITY; BIOMEDICAL ENGINEERING; MONOCLONAL ANTIBODIES; NANOPARTICLES; PATTERN RECOGNITION SYSTEMS;

SURFACES;

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOMATERIAL; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; DENDRIMER; MANNOSE BINDING LECTIN; NANOPARTICLE; POLYMER; PROPERDIN; SPHINGOLIPID ACTIVATOR PROTEIN 2;

BIOCOMPATIBILITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI INFECTION; GENE MUTATION; GENETIC POLYMORPHISM; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MATERIAL COATING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SEPSIS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS;

EID: 80052160688     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.010     Document Type: Review

References (173)

1. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
2. Mollnes T.E., Song W.C., Lambris J.D. Complement in inflammatory tissue damage and disease. Trends Immunol. 2002, 23:61-64.
3. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
4. Biro A., Rovo Z., Papp D., Cervenak L., Varga L., Fust G., Thielens N.M., Arlaud G.J., Prohaszka Z. Studies on the interactions between C-reactive protein and complement proteins. Immunology 2007, 121:40-50.
5. Kang Y.S., Do Y., Lee H.K., Park S.H., Cheong C., Lynch R.M., Loeffler J.M., Steinman R.M., Park C.G. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 2006, 125:47-58.
6. Paidassi H., Tacnet-Delorme P., Garlatti V., Darnault C., Ghebrehiwet B., Gaboriaud C., Arlaud G.J., Frachet P. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J. Immunol. 2008, 180:2329-2338.
7. Roos A., Bouwman L.H., Munoz J., Zuiverloon T., Faber-Krol M.C., Fallaux-van den Houten F.C., Klar-Mohamad N., Hack C.E., Tilanus M.G., Daha M.R. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol. 2003, 39:655-668.
8. Garred P., Larsen F., Seyfarth J., Fujita R., Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7:85-94.
9. Krarup A., Thiel S., Hansen A., Fujita T., Jensenius J.C. L-ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 2004, 279:47513-47519.
10. Tack B.F., Harrison R.A., Janatova J., Thomas M.L., Prahl J.W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:5764-5768.
11. Pangburn M.K., Muller-Eberhard H.J. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 1980, 152:1102-1114.
12. Bexborn F., Andersson P.O., Chen H., Nilsson B., Ekdahl K.N. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H(2)O)Bb). Mol. Immunol. 2008, 45:2370-2379.
13. Harboe M., Ulvund G., Vien L., Fung M., Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138:439-446.
14. Harboe M., Garred P., Karlstrom E., Lindstad J.K., Stahl G.L., Mollnes T.E. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol. 2009, 47:373-380.
15. Fearon D.T., Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 1975, 142:856-863.
16. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
17. Kimura Y., Miwa T., Zhou L., Song W.C. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008, 111:732-740.
18. Stover C.M., Luckett J.C., Echtenacher B., Dupont A., Figgitt S.E., Brown J., Mannel D.N., Schwaeble W.J. Properdin plays a protective role in polymicrobial septic peritonitis. J. Immunol. 2008, 180:3313-3318.
19. Kemper C., Atkinson J.P., Hourcade D.E. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 2010, 28:131-155.
20. Hourcade D.E. Properdin and complement activation: a fresh perspective. Curr. Drug Targets 2008, 9:158-164.
21. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
22. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
23. Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816-1820.
24. Morgan H.P., Schmidt C.Q., Guariento M., Blaum B.S., Gillespie D., Herbert A.P., Kavanagh D., Mertens H.D., Svergun D.I., Johansson C.M., Uhrin D., Barlow P.N., Hannan J.P. Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 2011, 18:463-470.
25. Roumenina L.T., Loirat C., Dragon-Durey M.A., Halbwachs-Mecarelli L., Sautes-Fridman C., Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 2011, 365:8-26.
26. Strey C.W., Markiewski M., Mastellos D., Tudoran R., Spruce L.A., Greenbaum L.E., Lambris J.D. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 2003, 198:913-923.
27. Markiewski M.M., Mastellos D., Tudoran R., DeAngelis R.A., Strey C.W., Franchini S., Wetsel R.A., Erdei A., Lambris J.D. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 2004, 173:747-754.
28. Markiewski M.M., DeAngelis R.A., Strey C.W., Foukas P.G., Gerard C., Gerard N., Wetsel R.A., Lambris J.D. The regulation of liver cell survival by complement. J. Immunol. 2009, 182:5412-5418.
29. Clark A., Weymann A., Hartman E., Turmelle Y., Carroll M., Thurman J.M., Holers V.M., Hourcade D.E., Rudnick D.A. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol. Immunol. 2008, 45:3125-3132.
30. Lachmann P.J., Smith R.A. Taking complement to the clinic-has the time finally come?. Scand. J. Immunol. 2009, 69:471-478.
31. Leite M.I., Waters P., Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010, 43:371-379.
32. Pedchenko V., Bondar O., Fogo A.B., Vanacore R., Voziyan P., Kitching A.R., Wieslander J., Kashtan C., Borza D.B., Neilson E.G., Wilson C.B., Hudson B.G. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N. Engl. J. Med. 2010, 363:343-354.
33. Ji H., Ohmura K., Mahmood U., Lee D.M., Hofhuis F.M., Boackle S.A., Takahashi K., Holers V.M., Walport M., Gerard C., Ezekowitz A., Carroll M.C., Brenner M., Weissleder R., Verbeek J.S., Duchatelle V., Degott C., Benoist C., Mathis D. Arthritis critically dependent on innate immune system players. Immunity 2002, 16:157-168.
34. Ward P.A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 2004, 4:133-142.
35. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
36. Barratt-Due A., Thorgersen E.B., Lindstad J.K., Pharo A., Brekke O.L., Christiansen D., Lambris J.D., Mollnes T.E. Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood. Mol. Immunol. 2010, 47:1774-1782.
37. Hawlisch H., Kohl J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 2006, 43:13-21.
38. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010, 31:154-163.
39. Mollnes T.E., Christiansen D., Brekke O.L., Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 2008, 632:253-263.
40. Lappegard K.T., Christiansen D., Pharo A., Thorgersen E.B., Hellerud B.C., Lindstad J., Nielsen E.W., Bergseth G., Fadnes D., Abrahamsen T.G., Hoiby E.A., Schejbel L., Garred P., Lambris J.D., Harboe M., Mollnes T.E. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15861-15866.
41. Damman J., Daha M.R., van Son W.J., Leuvenink H.G., Ploeg R.J., Seelen M.A. Crosstalk between complement and toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am. J. Transplant. 2011, 11:660-669.
42. Figueroa J., Andreoni J., Densen P. Complement deficiency states and meningococcal disease. Immunol. Res. 1993, 12:295-311.
43. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:1676-1687.
44. Skerka C., Licht C., Mengel M., Uzonyi B., Strobel S., Zipfel P.F., Jozsi M. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles. Mol. Immunol. 2009, 46:2801-2807.
45. Levy M., Halbwachs-Mecarelli L., Gubler M.C., Kohout G., Bensenouci A., Niaudet P., Hauptmann G., Lesavre P. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int. 1986, 30:949-956.
46. Hogasen K., Jansen J.H., Mollnes T.E., Hovdenes J., Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J. Clin. Invest 1995, 95:1054-1061.
47. Vernon K.A., Pickering M.C., Cook T. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease. Contrib. Nephrol. 2011, 169:198-210.
48. Wang J., Ohno-Matsui K., Yoshida T., Kojima A., Shimada N., Nakahama K., Safranova O., Iwata N., Saido T.C., Mochizuki M., Morita I. Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from Drusen. J. Immunol. 2008, 181:712-720.
49. Kaarniranta K., Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J. Mol. Med. 2009, 87:117-123.
50. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256-1264.
51. Mollnes T.E., Kirschfink M. Strategies of therapeutic complement inhibition. Mol. Immunol. 2006, 43:107-121.
52. Socha M., Bartecki P., Passirani C., Sapin A., Damge C., Lecompte T., Barre J., El G.F., Maincent P. Stealth nanoparticles coated with heparin as peptide or protein carriers. J. Drug Target 2009, 17:575-585.
53. Meerasa A., Huang J.G., Gu F.X. CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction. Curr. Drug Deliv. 2011, 8:290-298.
54. Zwirner J., Felber E., Reiter C., Riethmuller G., Feucht H.E. Deposition of complement activation products on plastic-adsorbed immunoglobulins. A simple ELISA technique for the detection of defined complement deficiencies. J. Immunol. Methods 1989, 124:121-129.
55. Fredrikson G.N., Truedsson L., Sjoholm A.G. New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence. J. Immunol. Methods 1993, 166:263-270.
56. McGrath F.D., Brouwer M.C., Arlaud G.J., Daha M.R., Hack C.E., Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J. Immunol. 2006, 176:2950-2957.
57. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 2005, 296:187-198.
58. Mollnes T.E., Jokiranta T.S., Truedsson L., Nilsson B., Rodriguez Test C.S. Complement analysis in the 21st century. Mol. Immunol. 2007, 44:3838-3849.
59. Sjoholm A.G., Selander B., Ostenson S., Holmstrom E., Soderstrom C. Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation. APMIS 1991, 99:1120-1128.
60. Petersen S.V., Thiel S., Jensen L., Steffensen R., Jensenius J.C. An assay for the mannan-binding lectin pathway of complement activation. J. Immunol. Methods 2001, 257:107-116.
61. Kuipers S., Aerts P.C., Sjoholm A.G., Harmsen T., van D.H. A hemolytic assay for the estimation of functional mannose-binding lectin levels in human serum. J. Immunol. Methods 2002, 268:149-157.
62. Munkvad S., Jespersen J., Gram J., Overgaard K., Ranby M. Effects of methylamine and heparin on a rapid chromogenic assay of C1-esterase inhibitor in plasma. Clin. Chem. 1990, 36:737-741.
63. Sanchez-Corral P., Gonzalez-Rubio C., Rodriguez Test C.S. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 2004, 41:81-84.
64. Janzi M., Odling J., Pan-Hammarstrom Q., Sundberg M., Lundeberg J., Uhlen M., Hammarstrom L., Nilsson P. Serum microarrays for large scale screening of protein levels. Mol. Cell Proteomics 2005, 4:1942-1947.
65. Borrebaeck C.A. Antibody microarray-based oncoproteomics. Expert. Opin. Biol. Ther. 2006, 6:833-838.
66. Wingren C., Borrebaeck C.A. Antibody microarrays: current status and key technological advances. OMICS 2006, 10:411-427.
67. Ingvarsson J., Lindstedt M., Borrebaeck C.A., Wingren C. One-step fractionation of complex proteomes enables detection of low abundant analytes using antibody-based microarrays. J. Proteome. Res. 2006, 5:170-176.
68. Ingvarsson J., Larsson A., Sjoholm A.G., Truedsson L., Jansson B., Borrebaeck C.A., Wingren C. Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J. Proteome. Res. 2007, 6:3527-3536.
69. Doucet A., Overall C.M. Broad coverage identification of multiple proteolytic cleavage site sequences in complex high molecular weight proteins using quantitative proteomics as a complement to edman sequencing. Mol. Cell Proteomics 2011, 10. M110.003533. Epub 2010 Sep 28.
70. Freue G.V., Sasaki M., Meredith A., Gunther O.P., Bergman A., Takhar M., Mui A., Balshaw R.F., Ng R.T., Opushneva N., Hollander Z., Li G., Borchers C.H., Wilson-McManus J., McManus B.M., Keown P.A., McMaster W.R. Proteomic signatures in plasma during early acute renal allograft rejection. Mol. Cell Proteomics 2010, 9:1954-1967.
71. Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J., Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 2002, 31:424-428.
72. Appel G.B., Cook H.T., Hageman G., Jennette J.C., Kashgarian M., Kirschfink M., Lambris J.D., Lanning L., Lutz H.U., Meri S., Rose N.R., Salant D.J., Sethi S., Smith R.J., Smoyer W., Tully H.F., Tully S.P., Walker P., Welsh M., Wurzner R., Zipfel P.F. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 2005, 16:1392-1403.
73. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., de Rodriguez C.S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest 2010, 120:3702-3712.
74. Saunders R.E., Goodship T.H., Zipfel P.F., Perkins S.J. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum. Mutat. 2006, 27:21-30.
75. Atkinson J.P., Goodship T.H. Complement factor H and the hemolytic uremic syndrome. J. Exp. Med. 2007, 204:1245-1248.
76. Kaur I., Hussain A., Hussain N., Das T., Pathangay A., Mathai A., Hussain A., Nutheti R., Nirmalan P.K., Chakrabarti S. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. Invest Ophthalmol. Vis. Sci. 2006, 47:3729-3735.
77. Hakobyan S., Harris C.L., Tortajada A., de Goicochea J.E., Garcia-Layana A., Fernandez-Robredo P., de Rodriguez C.S., Morgan B.P. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol. Vis. Sci. 2008, 49:1983-1990.
78. Mollnes T.E., Lea T., Harboe M., Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 1985, 22:183-195.
79. Mollnes T.E., Lea T., Froland S.S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 1985, 22:197-202.
80. Mollnes T.E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 1993, 91:295-300.
81. Mollnes T.E., Kirschfink M. Complement analysis in clinic and research. Adv. Exp. Med. Biol. 2006, 586:361-380.
82. Wagner J.L., Hugli T.E. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal. Biochem. 1984, 136:75-88.
83. Oppermann M., Gotze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994, 82:516-521.
84. Teisner B., Brandslund I., Grunnet N., Hansen L.K., Thellesen J., Svehag S.E. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation. J. Clin. Lab. Immunol. 1983, 12:63-67.
85. Mollnes T.E. Early- and late-phase activation of complement evaluated by plasma levels of C3d, g and the terminal complement complex. Complement 1985, 2:156-164.
86. Palarasah Y., Skjodt K., Brandt J., Teisner B., Koch C., Vitved L., Skjoedt M.O. Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3. J. Immunol. Methods 2010, 362:142-150.
87. Deppisch R., Schmitt V., Bommer J., Hansch G.M., Ritz E., Rauterberg E.W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 1990, 37:696-706.
88. Mollnes T.E., Lea T., Mellbye O.J., Pahle J., Grand O., Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986, 29:715-721.
89. Mollnes T.E., Haga H.J., Brun J.G., Nielsen E.W., Sjoholm A., Sturfeldt G., Martensson U., Bergh K., Rekvig O.P. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford) 1999, 38:933-940.
90. Sprott H., Muller-Ladner U., Distler O., Gay R.E., Barnum S.R., Landthaler M., Scholmerich J., Lang B., Gay S. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J. Rheumatol. 2000, 27:402-404.
91. Horigome I., Seino J., Sudo K., Kinoshita Y., Saito T., Yoshinaga K. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Clin. Exp. Immunol. 1987, 70:417-424.
92. Nagy G., Brozik M., Varga L., Fust G., Kirschfink M., Kiss E., Gergely P. Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 2000, 9:19-25.
93. Quigg R.J. Complement and autoimmune glomerular diseases. Curr. Dir. Autoimmun. 2004, 7:165-180.
94. Ovrum E., Fosse E., Mollnes T.E., Am H.E., Tangen G., Abdelnoor M., Ringdal M.A., Oystese R., Venge P. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur. J. Cardiothorac. Surg. 1996, 10:54-60.
95. Baufreton C., Moczar M., Intrator L., Jansen P.G., V.H.te, Le B.P., Farcet J.P., Wildevuur C.R., Loisance D.Y. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Perfusion 1998, 13:419-427.
96. Hoel T.N., Videm V., Mollnes T.E., Saatvedt K., Brosstad F., Fiane A.E., Fosse E., Svennevig J.L. Off-pump cardiac surgery abolishes complement activation. Perfusion 2007, 22:251-256.
97. Mollnes T.E., Vandvik B., Lea T., Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J. Neurol. Sci. 1987, 78:17-28.
98. Mollnes T.E., Fosse E. The complement system in trauma-related and ischemic tissue damage: a brief review. Shock 1994, 2:301-310.
99. Schreiber H., Rittirsch D., Flierl M., Brueckner U., Schneider M., Weiss M., Gebhard F., Huber-Lang M. Complement activation during sepsis in humans. Adv. Exp. Med. Biol. 2006, 586:217-226.
100. Brandtzaeg P., Mollnes T.E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 1989, 160:58-65.
101. Lindenskov P.H., Castellheim A., Aamodt G., Saugstad O.D., Mollnes T.E. Complement activation reflects severity of meconium aspiration syndrome in newborn pigs. Pediatr. Res. 2004, 56:810-817.
102. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 1985, 37:151-216.
103. Fure H., Nielsen E.W., Hack C.E., Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 1997, 46:553-557.
104. Nuijens J.H., Huijbregts C.C., Eerenberg-Belmer A.J., Abbink J.J., Strack van Schijndel R.J., Felt-Bersma R.J., Thijs L.G., Hack C.E. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988, 72:1841-1848.
105. Petersen S.V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., Jensenius J.C. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 2000, 37:803-811.
106. Wolbink G.J., Bollen J., Baars J.W., ten Berge R.J., Swaak A.J., Paardekooper J., Hack C.E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 1993, 163:67-76.
107. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
108. Garred P., Mollnes T.E., Lea T., Fischer E. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand. J. Immunol. 1988, 27:319-327.
109. Mollnes T.E., Riesenfeld J., Garred P., Nordstrom E., Hogasen K., Fosse E., Gotze O., Harboe M. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs 1995, 19:909-917.
110. Lappegard K.T., Bergseth G., Riesenfeld J., Pharo A., Magotti P., Lambris J.D., Mollnes T.E. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J. Biomed. Mater. Res. A 2008, 87:129-135.
111. Bergseth G., Lambris J.D., Mollnes T.E., Lappegard K.T. Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person. Ann. Thorac. Surg. 2011, 91:527-533.
112. Atkinson J.P., Farries T. Separation of self from non-self in the complement system. Immunol. Today 1987, 8:212-215.
113. Wu Y.Q., Qu H., Sfyroera G., Tzekou A., Kay B.K., Nilsson B., Nilsson E.K., Ricklin D., Lambris J.D. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 2011, 186:4269-4277.
114. Johannessen E., Krushinitskaya O., Sokolov A., Philipp H., Hoogerwerf A., Hinderling C., Kautio K., Lenkkeri J., Strommer E., Kondratyev V., Tonnessen T.I., Mollnes T.E., Jakobsen H., Zimmer E., Akselsen B. Toward an injectable continuous osmotic glucose sensor. J. Diabetes Sci. Technol. 2010, 4:882-892.
115. Sokolov A., Hellerud B.C., Pharo A., Johannessen E.A., Mollnes T.E. Complement activation by candidate biomaterials of an implantable microfabricated medical device. J. Biomed. Mater. Res. B. Appl. Biomater. 2011, Epub ahead of print June 6, 2011.
116. Andersen A.J., Hashemi S.H., Andresen T.L., Hunter A.C., Moghimi S.M. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 2009, 5:364-372.
117. Salvador-Morales C., Zhang L., Langer R., Farokhzad O.C. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30:2231-2240.
118. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
119. Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control Release 2010, 146:175-181.
120. Vauthier C., Persson B., Lindner P., Cabane B. Protein adsorption and complement activation for di-block copolymer nanoparticles. Biomaterials 2011, 32:1646-1656.
121. Thomas S.N., d.van, V, O'Neil C.P., Reddy S.T., Yu S.S., Giorgio T.D., Swartz M.A., Hubbell J.A. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 2011, 32:2194-2203.
122. Waelgaard L., Thorgersen E.B., Line P.D., Foss A., Mollnes T.E., Tonnessen T.I. Microdialysis monitoring of liver grafts by metabolic parameters, cytokine production, and complement activation. Transplantation 2008, 86:1096-1103.
123. Buras J.A., Rice L., Orlow D., Pavlides S., Reenstra W.R., Ceonzo K., Stahl G.L. Inhibition of C5 or absence of C6 protects from sepsis mortality. Immunobiology 2004, 209:629-635.
124. Padilla N.D., van Vliet A.K., Schoots I.G., Valls S.M., Maas M.A., Peltenburg E.E., V.A.de, Niessen H.W., Hack C.E., van Gulik T.M. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 2007, 142:722-733.
125. Redl H., Bahrami S. Large animal models: baboons for trauma, shock, and sepsis studies. Shock 2005, 24(Suppl. 1):88-93.
126. Knight A. The beginning of the end for chimpanzee experiments?. Philos. Ethics Humanit. Med. 2008, 3:16.
127. Knight A. The poor contribution of chimpanzee experiments to biomedical progress. J. Appl. Anim. Welf. Sci. 2007, 10:281-308.
128. Bailey J. An examination of chimpanzee use in human cancer research. Altern. Lab. Anim. 2009, 37:399-416.
129. Parker H.G., Shearin A.L., Ostrander E.A. Man's best friend becomes biology's best in show: genome analyses in the domestic dog. Annu. Rev. Genet. 2010, 44:309-336.
130. Jiang Z., Rothschild M.F. Swine genome science comes of age. Int. J. Biol. Sci. 2007, 3:129-131.
131. Fan B., Gorbach D.M., Rothschild M.F. The pig genome project has plenty to squeal about. Cytogenet Genome Res. 2011, 9-18.
132. Lunney J.K. Advances in swine biomedical model genomics. Int. J. Biol. Sci. 2007, 3:179-184.
133. Swindle M.M., Smith A.C., Hepburn B.J. Swine as models in experimental surgery. J. Invest Surg. 1988, 1:65-79.
134. Linton S. Animal models of inherited complement deficiency. Mol. Biotechnol. 2001, 18:135-148.
135. Lesher A.M., Song W.C. Review: complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010, 15:663-675.
136. Michie H.R. The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. J. Antimicrob. Chemother. 1998, 41(Suppl. A):47-49.
137. Mollnes T.E., Lachmann P.J. Regulation of complement. Scand. J. Immunol. 1988, 27:127-142.
138. Castellheim A., Thorgersen E.B., Hellerud B.C., Pharo A., Johansen H.T., Brosstad F., Gaustad P., Brun H., Fosse E., Tonnessen T.I., Nielsen E.W., Mollnes T.E. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand. J. Immunol. 2008, 68:75-84.
139. Rittirsch D., Huber-Lang M.S., Flierl M.A., Ward P.A. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 2009, 4:31-36.
140. Zipfel P.F., Heinen S., Jozsi M., Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 2006, 43:97-106.
141. Diepenhorst G.M., van Gulik T.M., Hack C.E. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann. Surg. 2009, 249:889-899.
142. Arumugam T.V., Magnus T., Woodruff T.M., Proctor L.M., Shiels I.A., Taylor S.M. Complement mediators in ischemia-reperfusion injury. Clin. Chim. Acta 2006, 374:33-45.
143. Zacharia B.E., Hickman Z.L., Grobelny B.T., DeRosa P.A., Ducruet A.F., Connolly E.S. Complement inhibition as a proposed neuroprotective strategy following cardiac arrest. Mediators Inflamm. 2009, 2009. ID: 124384.
144. Banz Y., Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann. Med. 2011, E-published. Jan 24, 2011.
145. Wendel H.P., Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur. J. Cardiothorac. Surg. 1999, 16:342-350.
146. Nilsson L., Storm K.E., Thelin S., Bagge L., Hultman J., Thorelius J., Nilsson U. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif. Organs 1990, 14:46-48.
147. Saito N., Motoyama S., Sawamoto J. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif. Organs 2000, 24:547-554.
148. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
149. Wilson G.S., Gifford R. Biosensors for real-time in vivo measurements. Biosens. Bioelectron. 2005, 20:2388-2403.
150. Tanaka S., Suzuki T., Nishioka K. Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes. J. Immunol. Methods 1986, 86:161-170.
151. Tanaka S., Kitamura F., Suzuki T. Studies on the hemolytic activity of the classical and alternative pathway of complement in various animal species. Complement 1987, 4:33-41.
152. Salvesen B., Mollnes T.E. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Mol. Immunol. 2009, 46:1620-1625.
153. Link C., Hawlisch H., z.Meyer V., Gyleruz S., Nagel E., Kohl J. Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation. Mol. Immunol. 1999, 36:1235-1247.
154. Hawlisch H., z.Meyer V., Bautsch W., Klos A., Kohl J. Guinea pig C3 specific rabbit single chain Fv antibodies from bone marrow, spleen and blood derived phage libraries. J. Immunol. Methods 2000, 236:117-131.
155. Bergh K., Iversen O.J. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a. Scand. J. Immunol. 1989, 29:333-341.
156. Mastellos D., Prechl J., Laszlo G., Papp K., Olah E., Argyropoulos E., Franchini S., Tudoran R., Markiewski M., Lambris J.D., Erdei A. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol. Immunol. 2004, 40:1213-1221.
157. Schulze M., Baker P.J., Perkinson D.T., Johnson R.J., Ochi R.F., Stahl R.A., Couser W.G. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int. 1989, 35:60-68.
158. Thorgersen E.B., Ghebremariam Y.T., Thurman J.M., Fung M., Nielsen E.W., Holers V.M., Kotwal G.J., Mollnes T.E. Candidate inhibitors of porcine complement. Mol. Immunol. 2007, 44:1827-1834.
159. Lachmann P.J. Preparing serum for functional complement assays. J. Immunol. Methods 2010, 352:195-197.
160. Mollnes T.E., Garred P., Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin. Exp. Immunol. 1988, 73:484-488.
161. Stove S., Klos A., Bautsch W., Kohl J. Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. J. Immunol. Methods 1995, 182:1-5.
162. Golan M.D., Burger R., Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J. Immunol. 1982, 129:445-447.
163. Ichihara C., Nakamura T., Nagasawa S., Koyama J. Monoclonal anti-human C4b antibodies: stabilization and inhibition of the classical-pathway C3 convertase. Mol. Immunol. 1986, 23:151-157.
164. Burger R., Bader A., Kirschfink M., Rother U., Schrod L., Worner I., Zilow G. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clin. Exp. Immunol. 1987, 68:703-711.
165. Burger R., Zilow G., Bader A., Friedlein A., Naser W. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential. J. Immunol. 1988, 141:553-558.
166. Nilsson B., Svensson K.E., Inganas M., Nilsson U.R. A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J. Immunol. Methods 1988, 107:281-287.
167. Lachmann P.J., Pangburn M.K., Oldroyd R.G. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J. Exp. Med. 1982, 156:205-216.
168. Garred P., Mollnes T.E., Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand. J. Immunol. 1988, 27:329-335.
169. Hack C.E., Paardekooper J., Smeenk R.J., Abbink J., Eerenberg A.J., Nuijens J.H. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J. Immunol. 1988, 141:1602-1609.
170. Takeda J., Kinoshita T., Takata Y., Kozono H., Tanaka E., Hong K., Inoue K. Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies. J. Immunol. Methods 1987, 101:265-270.
171. Bergh K., Iversen O.J. Production of monoclonal antibodies against the human anaphylatoxin C5a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a des Arg in plasma. J. Immunol. Methods 1992, 152:79-87.
172. Falk R.J., Dalmasso A.P., Kim Y., Tsai C.H., Scheinman J.I., Gewurz H., Michael A.F. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J. Clin. Invest 1983, 72:560-573.
173. Oppermann M., Wurzner R. Modern determination of complement activation. Semin. Thromb. Hemost. 2010, 36:611-619.